


Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



SINO BIOPHARMACEUTICAL LIMITED
中國生物製藥有限公司

(Incorporated in the Cayman Islands with limited liability)

Website: www.sinobiopharm.com

(Stock code: 1177)

VOLUNTARY ANNOUNCEMENT
PROGRESS UPDATE ON THE “IMPLEMENTATION OF
SHARE INCENTIVE SCHEME BY CHIA TAI TIANQING”

Reference is made to the announcement of Sino Biopharmaceutical Limited (the “**Company**”) dated 7 May 2024, in relation to the implementation of the Share Incentive Scheme by its subsidiary Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (“**Chia Tai Tianqing**”) (the “**Announcement**”). Unless the context otherwise requires, the capitalized terms used herein shall have the same meanings as defined in the Announcement.

The Board of the Company announces that, from 7 May 2024 to 30 September 2024, Chia Tai Tianqing has purchased an aggregate of 187,385,000 Shares under the Share Incentive Scheme for an aggregate consideration of approximately HK\$550,572,130, with remaining share purchase amount of approximately RMB500 million. Chia Tai Tianqing will continue to purchase Shares pursuant to this Share Incentive Scheme depending on market conditions.

The Share Incentive Scheme aims to further establish and optimize the benefits sharing mechanism among Chia Tai Tianqing and its employees, motivate the enthusiasm and creativity of the employees, enhance employee cohesion and competitiveness of Chia Tai Tianqing, as well as promoting the long-term, continuous and healthy development of Chia Tai Tianqing.

The implementation of the Share Incentive Scheme by Chia Tai Tianqing, being a major subsidiary of the Company, at this point of time demonstrates its confidence in the business development prospects of the Company and the intrinsic value of the Shares. The Board believes that the Share Incentive Scheme will provide impetus for Chia Tai Tianqing to accelerate its growth and achieve better performance.

By order of the Board
Sino Biopharmaceutical Limited
Tse, Theresa Y Y
Chairwoman

Hong Kong, 4 October 2024

As at the date of this announcement, the Board of the Company comprises six executive directors, namely Ms. Tse, Theresa Y Y, Mr. Tse Ping, Ms. Cheng Cheung Ling, Mr. Tse, Eric S Y, Mr. Tse Hsin, and Mr. Tian Zhoushan, and five independent non-executive directors, namely Mr. Lu Zhengfei, Mr. Li Dakui, Ms. Lu Hong, Mr. Zhang Lu Fu and Dr. Li Kwok Tung Donald.